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Abstract A chemokine receptor, CXCR4, and its endogenous
ligand, stromal cell-derived factor-1 (SDF-1), have been recog-
nized to be involved in the metastasis of several types of cancers.
T140 analogs are peptidic CXCR4 antagonists composed of 14
amino acid residues that were previously developed as anti-HIV
agents having inhibitory activity against HIV-entry through its
co-receptor, CXCR4. Herein, we report that these compounds
e¡ectively inhibited SDF-1-induced migration of human breast
cancer cells (MDA-MB-231), human leukemia T cells (Sup-T1)
and human umbilical vein endothelial cells at concentrations of
10^100 nM in vitro. Furthermore, slow release administration
by subcutaneous injection using an Alzet osmotic pump of a
potent and bio-stable T140 analog, 4F-benzoyl-TN14003, gave
a partial, but statistically signi¢cant (P90.05 (t-test)) reduc-
tion in pulmonary metastasis of MDA-MB-231 in SCID mice,
even though no attempt was made to inhibit other important
targets such as CCR7. These results suggest that T140 analogs
have potential use for cancer therapy, and that small molecular
CXCR4 antagonists could potentially replace neutralizing anti-
bodies as anti-metastatic agents for breast cancer.
6 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Cancer metastasis represents the most serious step in the
progress of this disease. There have been ample recent prece-
dents supporting the involvement of chemokine receptors,
such as CXCR4 and CCR7, in progression and metastasis
of cancer cells [1^13]. CXCR4 and CCR7 belong to a 7TM
GP-CR family that normally acts as receptors for chemokines,
stromal cell-derived factor-1 (SDF-1/CXCL12) [14^17] and
CCL21 [18^20], respectively. Chemokines belong to a chemo-
tactic cytokine family that plays fundamental roles in the
physiology of in£ammatory processes by attracting and sim-
ulating leukocytes. Chemokine-induced leukocyte tra⁄cking
shares similarities with cancer cell migration and metastasis
[2]. We have reported that SDF-1 mRNA is expressed in
pancreatic cancer tissues, while CXCR4 mRNA is expressed
both in pancreatic cancer tissues and in pancreatic cancer cell
lines, and we have indicated that interactions between CXCR4
and SDF-1 are involved in pancreatic cancer progression [1].
Breast cancer and melanoma have similar metastatic patterns
in terms of organ selectivity that involves lymph nodes, bone
marrow, lung and liver. Mu«ller reported that chemokine/che-
mokine receptor systems, such as SDF-1/CXCR4 and CCL21/
CCR7 (and CCL27/CCR10 in melanoma), have been associ-
ated with metastasis of breast cancer and melanoma [2].
CXCR4 and CCR7 (and CCR10 in melanoma) are highly
expressed in human breast cancer cells and malignant mela-
noma cells. Alternatively, SDF-1 and CCL21 (and CCL27 for
melanoma) show high levels of expression in lymph nodes,
bone marrow, lung and liver (and skin for melanoma), which
constitute the most common metastasis sites of breast cancer
and melanoma. In vitro, the interactions between CXCR4 and
SDF-1 and between CCR7 and CCL21 trigger actin polymer-
ization and pseudopodia formation and subsequently induce
invasion of malignant cells in breast cancer. In vivo, meta-
stasis of breast cancer cells can be inhibited by neutralization
using anti-CXCR4 antibodies in mice. According to recent
papers, the SDF/CXCR4 interaction axis is involved in cell
progression and metastasis of several types of cancer, includ-
ing prostate cancer [7], kidney cancer [8], neuroblastoma [4],
non-Hodgkin’s lymphoma [9], lung cancer [11], ovarian cancer
[6,10], multiple myeloma [5], and chronic lymphocytic leuke-
mia [12], in addition to pancreatic cancer, breast cancer and
melanoma [3,13], angiogenesis [21,22]. Prior to the discovery
of CXCR4 involvement in cancer progression and metastasis,
CXCR4 had already been identi¢ed as a co-receptor in asso-
ciation with CD4 that is involved in the entry of T cell line-
tropic (X4-) HIV-1 [23]. To date, we have developed several
CXCR4 antagonists as HIV-entry inhibitors. These include
T140 analogs [24^28]. T140 is a 14-residue peptide having a
single disul¢de bridge that possesses high anti-HIV and
CXCR4 antagonistic activities. Here, in order to evaluate
the potency of small molecule CXCR4 antagonists as anti-
cancer-metastatic agents we investigated whether T140 ana-
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logs inhibit migration of breast cancer, endothelial and leuke-
mia cells in vitro and breast cancer metastasis in vivo.
2. Materials and methods
2.1. Materials
T140 and its analogs, TC14012, TE14005 and 4F-benzoyl-
TN14003, were synthesized by methodology described elsewhere
[24,26^28].
2.2. Cell lines and cell culture
Jurkat T cell lymphomas (Jurkat E6-1 cells) were obtained from the
American Type Culture Collection (Manassas, VA, USA) and culti-
vated in RPMI 1640 medium supplemented with 10% fetal calf serum.
Human umbilical vein endothelial cells (HUVEC) were purchased
from Kurabo (Osaka, Japan). HUVEC were maintained in Endothe-
lial-SFM medium (Gibco BRL, Rockville, MD, USA) supplemented
with 2% heat-inactivated fetal bovine serum (FBS), 2.5 ng/ml basic
¢broblast growth factor (RpD systems, Minneapolis, MN, USA) and
10 ng/ml epidermal growth factor (Wako Pure Chemical Ind., Osaka,
Japan). MDA-MB-231 human breast adenocarcinoma cells and Sup-
T1 human T cell lymphoma were also obtained from the American
Type Culture Collection. MDA-MB-231 cells were maintained in Lei-
bovitz’s L-15 medium supplemented with 10% FBS. Sup-T1 cells were
maintained in RPMI1640 medium supplemented with 10% FBS.
2.3. Binding assay [29]
Jurkat cells were harvested and resuspended in the binding bu¡er
(Dulbecco’s PBS containing 20 mM HEPES and 0.5% bovine serum
albumin, pH 7.0). Binding reactions were performed at room temper-
ature for 1 h in the presence of 50 pM [125I]-SDF-1K (speci¢c activity:
2200 Ci/mmol, Perkin Elmer Life Sciences, Boston, MA, USA) and
various concentrations of peptide. Binding reactions were terminated
by ¢ltration over GF/C ¢lters that were washed with cold PBS, and
cell-associated radioactivity was counted by Top-count1 scintillation
counter (Perkin Elmer) (n=3).
2.4. RT-PCR
Poly A RNA extraction from cultured MDA-MB-231 cells was
performed with QuickPrep mRNA puri¢cation kit (Amersham Bio-
science, Piscataway, NJ, USA) according to the manufacturer’s pro-
cedure. Sense and antisense primers were prepared including:
CXCR4, 5P-ATCTGGAGAACCAGCGGTTA and 3P-ATGAGGA-
CACTGCTGTAGAG (459 bp); CCR7, 5P-TGGTGGCTCTCCTT-
GTCATT and 3P-GATGGCCACGTAGCGGTCAA (440 bp); L-ac-
tin, 5P-ATCGAGCACGGCATCGTCACCA and 3P-GAGGAGCT-
GGAAGCAGCCGT (495 bp). Samples underwent thermal cycling
at 94‡C for 30 s, 65‡C for 30 s and 72‡C for 1 min for 30 cycles.
Fragment detection was performed using 2% agarose gel electropho-
resis.
2.5. Cell migration assays [30]
Migration assays were performed in 24-well cell culture chambers
using inserts with 8-Wm pore membranes (Transwell, model 3422,
Corning Inc., Corning, NY, USA). Membranes were pre-coated
with bovine ¢bronectin (10 Wg/ml) (Yanagi Corp., Yamagata, Japan).
The lower chamber was ¢lled with migration bu¡er (DMEM/0.1%
BSA/12 mM HEPES) containing various concentrations of peptides
and SDF-1 (30 nM for Sup-T1 cells, 100 nM for MDA-MB-231 cells
and HUVEC) (RpD systems). Peptide solutions and cell suspension
(2U105 cells/well) were added to the upper chamber. When Sup-T1
cells were assayed, cell numbers in the lower chamber were counted
using a Coulter particle counter after incubation at 37‡C for 4 h.
When MDA-MB-231 cells and HUVEC were assayed, after incuba-
tion at 37‡C for 15 h, non-migrating cells on the upper surface were
¢xed and stained with 0.5% crystal violet in 25% methanol. The ¢lters
were washed in distilled water, and the crystal violet was eluted by
0.1 M sodium citrate in 50% ethanol. Migrating cells were estimated
by measuring OD550nm with a microplate reader (Corona Electric,
Ibaraki, Japan).
2.6. In vivo metastasis studies
CB-17 severe combined immunode¢cient (SCID) mice (5 week old,
female, Crea Japan Inc., Tokyo, Japan) were injected intravenously
into the tail vein with MDA-MB-231 breast carcinoma cells (106
cells). The day before transplantation, an Alzet pump (duration, 14
days, pumping rate, 0.25 Wl/h, Model 1002, ALZA Corp., Mountain
View, CA, USA) containing 80 mg/ml of 4F-benzoyl-TN14003 (100 Wl
in saline) or vehicle was implanted subcutaneously. On day 14, the
Alzet pump containing the same amounts of peptide was additionally
implanted subcutaneously. On day 28, mice were killed, and 0.2%
Evans blue solution was injected through trachea to stain the lungs
green. The lungs were extracted and ¢xed with Bouin’s ¢xative (picric
acid: folmalin: acetic acid= 15:5:1), and the tumor area was also
stained yellow. Ratios of tumor area to total area on the lung surface
were calculated from di¡erence of color between tumor and normal
lung area using image analyzing techniques (MAC scope, Mitani
Corp., Fukui, Japan).
2.7. Statistical analysis
Statistical signi¢cance of results in the migration assays was ana-
lyzed using Williams’ test (depending on homogeneity of variance). A
value of P9 0.025 was considered signi¢cant. Results of in vivo meta-
stasis assays were assessed with Student’s t-test. The level of signi¢-
cance was de¢ned as P9 0.05.
3. Results
3.1. Evaluation of CXCR4-binding potency of T140 analogs
Among several T140 analogs, TC14012, TE14005 and 4F-
benzoyl-TN14003 were utilized for this study (Table 1).
CXCR4-binding potencies of these compounds were examined
based on inhibition of [125I]-SDF-1 binding to CXCR4-ex-
pressing Jurkat cells. We have previously reported the strong
anti-HIV and CXCR4 antagonistic activities of these agents
[26^28]. TC14012 and TE14005 showed approximately the
same CXCR4-binding potency as that of T140, whereas 4F-
benzoyl-TN14003 exhibited slightly higher potency than T140.
These results are compatible with our previous reports.
3.2. CXCR4 and CCR7 mRNA expression
RT-PCR was performed using speci¢c primers to examine
CXCR4 and CCR7 mRNA expression in human breast car-
cinoma cell lines, MDA-MB-231. CXCR4 mRNA expression
was clearly detected in MDA-MB-231 whereas the presence of
CCR7 mRNA was minimal (Fig. 1).
3.3. Inhibition of migration of breast cancer, leukemia and
endothelial cells in vitro
As reported by Mu«ller [2], SDF-1/CXCL12 (100 nM)
doubled the migration of the CXCR4-positive, human breast
carcinoma cell line MDA-MB-231, as compared to control
(Fig. 2A,C,E). T140 analogs inhibited SDF-1-induced migra-
Fig. 1. CXCR4 and CCR7 mRNA expressions in human breast car-
cinoma cell lines, MDA-MB-231. Lane 1, CXCR4 mRNA expres-
sion; lane 2, CCR7 mRNA expression; lane 3, L-actin mRNA ex-
pression.
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tion of MDA-MB-231 in dose-dependent manners. At a con-
centration of 100 nM, TC14012, TE14005, and 4F-benzoyl-
TN14003 caused 68%, 64%, and 78% reductions, respectively,
of MDA-MB-231 chemotaxis induced by SDF-1 (100 nM).
These compounds also reduced SDF-1-induced migration of
Sup-T1 leukemia cells and HUVEC endothelial cells at a con-
centration of 10 nM (data shown, Fig. 2B: TC14012-HU-
VEC, Fig. 2D: 4F-benzoyl-TN14003-Sup-T1).
3.4. Reduction of pulmonary metastasis in SCID mice with
inoculation of MDA-MB-231 by slow release
administration of 4F-benzoyl-TN14003
E¡ect of the CXCR4 antagonist, 4F-benzoyl-TN14003, was
investigated by using experimental metastasis models of breast
cancer MDA-MB-231 cells. In this model, cells were injected
intravenously (i.v.) into the tail vein of SCID mice and
trapped in the lung through heart and pulmonary artery.
Four mice were administered 4F-benzoyl-TN14003 by s.c. in-
jection using an Alzet pump beginning from the day preceding
transplantation of MDA-MB-231. Seven mice were not ad-
ministered the agent as control models. By histological detec-
tion on day 28, agent-treated mice showed a relative suppres-
sion of tumor accumulation on lung surface based on the
metastasis of MDA-MB-231 cells, as compared to control
mice. Quantitative analyses revealed that ratios of tumor
area to total lung surface area in treated mice were statistically
smaller than those of control mice (Table 2). 4F-benzoyl-
TN14003 signi¢cantly reduced pulmonary metastasis of
MDA-MB-231 cells in SCID mice.
4. Discussion
CXCR4 represents an important therapeutic target for sev-
eral diseases, including AIDS, cancer and rheumatoid arthri-
tis. We have previously developed the 18- and 14-mer pep-
tides, T22 [31] and T140 [24], respectively, as speci¢c CXCR4
antagonists that prevent X4-HIV-1 entry mediated by this
coreceptor. T140 possesses the highest level of anti-HIV ac-
Table 1
Sequences and CXCR4-binding activity of T140 analogs
Compound Sequencea IC50 (nM)b
T140 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-OH 2.4
TC14012 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D-Cit-Pro-Tyr-Arg-Cit-Cys-Arg-NH2 2.9
TE14005 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D-Glu-Pro-Tyr-Arg-Cit-Cys-Arg-OH 2.2
4F-benzoyl-TN14003 4-£uorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2 0.99
aEach peptide has a single disul¢de bridge between Cys4 and Cys13.
bIC50 values are the concentrations for 50% inhibition of binding of [125I]-SDF-1 to CXCR4-expressing Jurkat cells. Data are mean values for
three experiments.
Fig. 2. E¡ects of T140 analogs on SDF-1-induced migration of MDA-MB-231, HUVE and Sup-T1 cells. MDA-MB-231 cells were treated by
SDF-1 (100 nM) and various concentrations of TC14012 (A), TE14005 (C) and 4F-benzoyl-TN14003 (E). HUVEC were treated by SDF-1 (100
nM) and various concentrations of TC14012 (B). Sup-T1 cells were treated by SDF-1 (30 nM) and various concentrations of 4F-benzoyl-
TN14003 (D). Control migrating cells in the absence and presence of SDF-1 are shown as (-) and (+), respectively. Data are expressed as
meansXS.D. (n=2). *P9 0.025 (Williams’ test).
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tivity among all the CXCR4 antagonists that have been re-
ported up to 1998. The Cit/Glu-substitution study based on
T140 has generated several e¡ective compounds, such as
TC14012 and TE14005, where the total positive charge, which
is related to cytotoxicity and non-speci¢c binding, has been
reduced from that of T140 [26,27]. TC14012 is completely
stable in mouse serum due to its C-terminally amidated
form. Furthermore, N-terminal acylation of T140 derivatives
by a 4-£uorobenzoyl group to yield 4F-benzoyl-TN14003 in-
creases anti-HIV activity and biostability in rat liver homog-
enate [28]. Since neutralization of SDF-1/CXCR4 interactions
by anti-CXCR4 antibodies signi¢cantly impairs metastasis of
breast cancer cells to lung and regional lymph nodes in mice
[2], development of speci¢c CXCR4 antagonists has been con-
sidered as a potential approach toward anti-metastatic agents.
In the present study, we investigated whether CXCR4 antag-
onists derived from HIV-coreceptor inhibitors show anti-can-
cer-metastatic activity in vitro and in vivo. TC14012 and
TE14005, which have CXCR4-binding ability comparable to
that of T140 (Table 1), were used for cell migration assays in
vitro. 4F-benzoyl-TN14003, which possesses relatively higher
binding ability and increased biostability, was used for cell
migration assays in vitro and metastasis studies in vivo.
Tumor cell invasion, including adhesion to matrix compo-
nents (integrin, laminin, ¢bronectin, vitronectin, selectin, etc.),
and migration through basement membranes, are signi¢cant
parts of the process of cancer metastasis [32]. Cell migration,
which is recognized as a critical step in metastasis, is partly
induced by chemokines, such as SDF-1 and CCL21. In MDA-
MB-231 human breast carcinoma cells, CXCR4 mRNA ex-
pression was con¢rmed (Fig. 1). Thus, SDF-1 induces migra-
tion of MDA-MB-231 cells through its interaction with
CXCR4 (Fig. 2A,C,E) [2]. T140 analogs inhibit SDF-1-in-
duced migration of MDA-MB-231 cells and Sup-T1 leukemia
cells in dose-dependent manners, suggesting that these com-
pounds might suppress tumor spread. Since TC14012 also
inhibits SDF-1-induced migration of HUVEC endothelial
cells, these compounds might also suppress tumor angiogene-
sis. These results prompted us to investigate whether T140
analogs suppress breast cancer metastasis in vivo.
Murakami reported that daily i.p. treatment with T22 [31]
reduces pulmonary metastasis in mice following inoculation of
CXCR4-transduced B16 melanoma cells, whereas T22 did not
block metastasis in mice following inoculation of wild type
B16 cells [13]. T22 inhibits CXCR4-mediated increase in mel-
anoma metastasis. In our present study, the s.c. administra-
tion of 4F-benzoyl-TN14003 using an Alzet pump-mediated
controlled slow release starting before transplantation of
MDA-MB-231 cells, signi¢cantly reduced the pulmonary
growth in the experimental metastasis model. This metastasis
model mainly re£ects the process of reattachment to distant
organ, migration, invasion and proliferation, not detachment
from primary organ and circulation. SDF-1 is strong chemo-
attractant factor on not only leukocytes but also various types
of tumor cells and did not show any e¡ects on the growth of
MDA-MB-231 cells (data not shown), indicating that the
metastasis suppression of 4F-benzoyl-TN14003 is due to the
inhibition of the SDF-1-induced migration of MDA-MB-231
cells into lung tissue. It is reasonable that the T140 analog did
not completely suppress metastasis (the decrease of tumor
area: 39.4% to 24.8%), since the T140 analog can only block
CXCR4 action but it cannot a¡ect CCR7 action, and cancer
metastasis is a process mediated by orchestration of several
factors as described above. However, this result strongly sug-
gests that small molecule CXCR4 antagonists, such as T140
analogs, could replace neutralizing anti-CXCR4 antibodies as
anti-metastatic agents for the treatment of breast cancer.
In conclusion, CXCR4 antagonists, T140 analogs, inhibit
SDF-1-induced migration of human breast cancer, leukemia
and endothelial cells in vitro, in a fashion relevant to tumor
spread and angiogenesis. Furthermore, a potent and bio-sta-
ble T140 analog, 4F-benzoyl-TN14003, reduced pulmonary
metastasis of breast cancer in SCID mice. The suppression
of SDF-1/CXCR4 interactions may represent a novel thera-
peutic strategy against cancer metastasis which involves this
ligand-receptor system. These CXCR4 antagonists as well as
other antagonists, including AMD3100 [33], ALX40-4C [34]
and KRH-1636 [35], have the potential of becoming promis-
ing anti-cancer agents. Since T140 is an inverse agonist for a
constitutively active mutant of CXCR4 and wild type CXCR4
and lacks partial agonistic activity (SDF-1-like activity) [36], it
and its analogs might have some advantage in clinical devel-
opment.
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